MoonLake Immunotherapeutics - Class A
Research MoonLake Immunotherapeutics - Class A (MLTX) on Bullrun: market cap USD 904.62M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMLTX
- ExchangeNASDAQ
- CountrySwitzerland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 904.62M
- Financial periodQ2 2026
- RevenueUSD 0
- Net income-USD 61.81M
- Free cash flow-USD 55.56M
Valuation Snapshot
latest market cap is USD 904.62M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 227.32M | -USD 196.04M | n/a | -3.53 | USD 334.52M | USD 74.10M | USD 304.48M |
| FY2024 | USD 0 | -USD 118.94M | -USD 117.11M | n/a | -1.89 | USD 180.43M | USD 0 | USD 446.83M |
| FY2023 | USD 0 | -USD 36.01M | -USD 43.06M | n/a | -0.73 | USD 451.17M | USD 3.70M | USD 495.68M |
| FY2022 | USD 0 | -USD 49.97M | -USD 55.91M | n/a | -1.7 | USD 39.51M | USD 0 | USD 48.90M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-09 | USD 904.62M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 940.70M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 3.42B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 3.62B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 409.26M | n/a | n/a | n/a |
About MoonLake Immunotherapeutics - Class A
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is MoonLake Immunotherapeutics - Class A's market cap?
MoonLake Immunotherapeutics - Class A's market capitalization is USD 904.62M.
What does MoonLake Immunotherapeutics - Class A do?
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.